## Hims & Hers Launches GLP-1 Supply Tracker to Address US Access Crisis
Hims & Hers Health, Inc. (HIMS), a leading health and wellness platform known for its obesity-related portfolio, is taking action to address the ongoing challenges Americans face in accessing branded GLP-1 medications. The company has launched a
GLP-1 Supply Tracker
, a platform designed to collect data from individuals experiencing difficulties obtaining these crucial medications. The initiative comes amidst ongoing concerns about the availability of GLP-1s, despite recent updates from the FDA.Last week, the FDA revised its shortage list to indicate that the .25 mg starter dose of semaglutide-based obesity medication Wegovy is now available in the US. This follows the removal of Eli Lilly and Co’s (LLY) tirzepatide from the shortage list last month. However, Hims & Hers has been collecting data on these access issues since September, revealing a significant problem.
The Data Speaks Volumes
Through their platform, Hims & Hers has gathered information from nearly 80,000 individuals reporting difficulties obtaining branded GLP-1s. The challenges are particularly acute in states with high obesity rates. For instance, nearly 5,000 customers in Texas alone have shared their struggles in acquiring the necessary treatment.
The company has been actively engaged in conversations with state and federal agencies, sharing their users’ experiences to advocate for policy improvements. The new GLP-1 Supply Tracker aims to provide a deeper understanding of nationwide access challenges. In its first week, the tracker has already received nearly 7,000 reports, with individuals experiencing difficulties obtaining medications containing semaglutide, the active ingredient in Novo Nordisk A/S’s (NVO) Ozempic and Wegovy, being particularly prevalent.
Advocating for Change
The GLP-1 Supply Tracker serves as a crucial data collection and advocacy resource. By providing the FDA with insights into the realities of healthcare access, the company hopes to influence policy changes that can improve the situation. The shortage of branded GLP-1 medications reflects a broader issue in the healthcare landscape, where supply often struggles to keep pace with surging demand.
Hims & Hers’ research highlights the severity of the problem. The company found that nearly 30% of its weight loss customers prescribed branded GLP-1s were unable to fill their prescriptions due to pharmacy shortages. This trend aligns with the growing awareness and demand for these treatments. The University of Southern California reported a 442% increase in semaglutide prescriptions from January 2021 to December 2023.
Continuing to Support Patients
Hims & Hers remains committed to supporting patients in need. In September, the company launched the Service Appreciation Initiative, offering compounded GLP-1 weight loss medications to eligible US military personnel, veterans, teachers, nurses, and first responders for as low as $99 per month.
The launch of the GLP-1 Supply Tracker demonstrates Hims & Hers’ commitment to advocating for improved healthcare access and addressing the urgent need for greater availability of these critical medications. The company’s efforts are crucial in ensuring that individuals seeking treatment for obesity can access the resources they need.
